ARS Pharmaceuticals, Inc. (SPRY) has reported solid financial results for the fourth quarter and full-year 2024, driven by the commercial launch of neffy, the first and only needle-free epinephrine treatment for severe allergic reactions. neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to The trade name for neffy in the EU is EURneffy. It is the first and...
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.